Full Text
PCN59 Cost-Effectiveness of Pazopanib Versus Sunitinib and Bevacizumab Associated to Interferon Alpha As First Line Treatments for Metastatic Renal Cell Carcinoma

Abstract

Authors

C. Pepe L. Paladini C. Sedlmayer M. Machado

Back to Volume 15, Issue 4
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×